It's the road to scientific data, and not the road to commercialization that we wanted.
I think strategic options are on the table, get to a point where there is M&A action with some validated proof.
There has been no changes in organizational structure/design that you would expect for a company headed into P3/pivotal trial.
In my mind MD has run out of lives. You can't go through this many strategic last minute shifts or c*ck ups without falling on your sword. Some would argue this is beyond his control, but it is time.
All of 2022 was promises to align the FDA, but I've seen none of that, which gets me angry on driving value catalysts.
Kiss goodbye to options. Kiss goodbye to PRV.
- Forums
- ASX - By Stock
- PER
- Ann: ATL1102 Revised Plans accelerate reporting of unblinded data
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-62
-
- There are more pages in this discussion • 290 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.0¢ | $63.52K | 777.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 97561 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 0.080 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
3 | 91500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 141000 | 2 |
0.086 | 106100 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |